Do steroids have anti‑coagulant properties?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Do Steroids Have Anticoagulant Properties?

No, steroids do not have anticoagulant properties—in fact, corticosteroids have procoagulant effects that increase thrombotic risk, while sex hormones (estrogen/progesterone) significantly increase venous thromboembolism risk 2-3 fold. 1

Corticosteroids and Coagulation

Procoagulant Effects

Corticosteroids activate the coagulation system rather than inhibit it:

  • Clotting factor elevation: Short-term glucocorticoid treatment (5 days of dexamethasone) increases factor VII by 13%, factor VIII by 27%, factor XI by 6%, and fibrinogen by 13% in healthy volunteers 2

  • Thrombin generation: A 10-day prednisolone course in healthy subjects significantly increases peak thrombin, velocity index, PAI-1, and von Willebrand factor compared to placebo, creating a procoagulant state 3

  • Maintained hemostatic balance: While glucocorticoids increase both procoagulant factors (VIII, IX, XI, XII) and anticoagulants (antithrombin, protein C), the overall hemostatic balance is maintained rather than shifted toward anticoagulation 4

Clinical Implications for Thrombosis Risk

Patients on corticosteroids require thromboprophylaxis, not reduced anticoagulation:

  • Patients with acute severe ulcerative colitis treated with high-dose intravenous corticosteroids (methylprednisolone 60 mg daily or hydrocortisone 100 mg 6-hourly) must receive prophylactic low-molecular weight heparin due to 2-3 fold higher VTE risk 5

  • The FDA drug label for methylprednisolone explicitly states: "The effect of methylprednisolone on oral anticoagulants is variable. There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids. Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect." 6

Context-Dependent Effects

The impact of glucocorticoids varies by clinical situation 7:

  • During active inflammation: Glucocorticoids increase PAI-1 (antifibrinolytic) while decreasing von Willebrand factor and fibrinogen
  • Peri-operative use: Inhibits the surgery-induced increase in tissue-type plasminogen activator
  • In healthy volunteers: Clear increases in factor VII, VIII, and XI activity

Sex Hormones (Estrogen/Progesterone)

These steroids have the strongest prothrombotic effects:

  • Combined estrogen-progesterone therapy increases thrombotic risk 2-3 fold compared to non-users 1
  • Hormone replacement therapy more than doubles VTE risk (RR 2.14; 95% CI 1.64-2.81) 1
  • Estrogen increases factor VII activity, D-dimer, and prothrombin F1.2 while decreasing antithrombin III and tissue factor pathway inhibitor 1

Critical Clinical Caveat

Bleeding risk with intranasal corticosteroids is local, not systemic:

  • Intranasal corticosteroids increase nosebleed risk (RR 2.74) through local mucosal effects, not systemic anticoagulation 8
  • This represents local tissue effects rather than systemic hemostatic changes

Practical Management

When prescribing corticosteroids:

  • Monitor coagulation indices if patient is on anticoagulants, as steroids can unpredictably enhance or diminish anticoagulant effects 6
  • Provide thromboprophylaxis for hospitalized patients on high-dose IV corticosteroids 5
  • Consider increased VTE risk in cancer patients receiving steroids combined with chemotherapy or antiangiogenic agents 1
  • Avoid assuming anticoagulant properties—the opposite is true for systemic effects

Related Questions

Is there a correlation between corticosteroid (cortisone) injections and thrombosis (blood clots)?
How do corticosteroids affect platelet adhesion and what precautions should be taken when prescribing them to patients at risk of thrombosis?
Can prednisone (corticosteroid) cause falsely negative D-Dimer (D-dimer test) results in patients with a history of autoimmune disorders, such as lupus or antiphospholipid syndrome?
How to manage steroid-induced capillary bleeding?
Does a one‑week course of prednisone increase the risk of deep vein thrombosis in an otherwise healthy patient?
What is the recommended desloratadine dosing for adults, children of different age groups, and patients with moderate to severe renal or hepatic impairment?
What does the presence of small hyperdense nodules in both lentiform (putamen‑globus pallidus) nuclei indicate and what is the appropriate diagnostic work‑up?
What is the appropriate work‑up and management for a patient presenting with headache and bilateral lentiform‑nucleus hyperdensities on CT?
Is the cardiovascular risk of capecitabine comparable to that of intravenous 5‑fluorouracil (5‑FU) in adult cancer patients, including those with modest baseline cardiac disease?
How should desmopressin (DDAVP) be used to safely correct hyponatremia and prevent rapid over‑correction in patients with water‑retention disorders such as SIADH or postoperative hyponatremia?
How should I adjust the patient‑controlled analgesia (PCA) pump settings (0.3 mg demand dose, 15‑minute lock‑out interval, 1 mg/h basal infusion, 2.2 mg/h hourly maximum) for a patient experiencing severe pain?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.